ArticleAntimicrobial agents and chemotherapy2006
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review.The Journal of antimicrobial chemotherapy · 2026Pooled it
- Review
- Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring.JAC-antimicrobial resistance · 2026Article
- Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study.Pharmaceutics · 2026Article
- New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.Pathogens (Basel, Switzerland) · 2024Review
- Therapeutic drug monitoring of glycopeptide antimicrobials: An overview of liquid chromatography-tandem mass spectrometry methods.Journal of mass spectrometry and advances in the clinical lab · 2024Review
- [Defining new therapeutic scenarios for oritavancin: severe bacteremic Staphylococcus aureus skin and soft tissue infection in a severely immunocompromised oncology patient].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments.Life (Basel, Switzerland) · 2023Review
- New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.Antimicrobial agents and chemotherapy · 2022Review
- Pharmacokinetics and pharmacodynamics of peptide antibiotics.Advanced drug delivery reviews · 2022Review
- Regulatory utility of pharmacometrics in the development and evaluation of antimicrobial agents and its recent progress in China.CPT: pharmacometrics & systems pharmacology · 2021Review
- Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible.Frontiers in pharmacology · 2020Article
- Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.Antimicrobial agents and chemotherapy · 2019Article
- Validation and Application of a Dried Blood Spot Ceftriaxone Assay.Antimicrobial agents and chemotherapy · 2016Article
- Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Drugs · 2015Review
- Oritavancin for acute bacterial skin and skin structure infections.Expert opinion on pharmacotherapy · 2015Review
- Oritavancin diphosphate.Hospital pharmacy · 2014Article
- Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Article
- Review
- Current and novel antibiotics against resistant Gram-positive bacteria.Infection and drug resistance · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bloodstream infections due to antimicrobial-resistant Staphylococcus aureus occur with increasing frequency and represent an important cause of morbidity and mortality. To date, the evaluation of pharmacokinetic-pharmacodynamic relationships for efficacy among patients with bacteremia has been limited. The objectives of these analyses were to evaluate relationships between microbiological and clinical responses for patients with S. aureus bacteremia and exposures for oritavancin, a novel bactericidal glycopeptide in development. Bayesian oritavancin exposure predictions, following treatment with 5, 6.5, 8, or 10 mg/kg of body weight/day, were derived using a validated population pharmacokinetic model for 55 patients with S. aureus bacteremia. Using classification and regression tree analysis, a breakpoint of the percentage of the dosing interval duration for which free-drug concentrations were above the MIC (free-drug % time > MIC) of 22% was identified for microbiological response; the probabilities of success greater than or equal to and less than this value were 93% and 76%, respectively. Using logistic regression, a relationship was found between microbiological response and free-drug % time > MIC (odds ratio = 4.42, P = 0.09, and odds ratio = 8.84, P = 0.05, when one patient, a medical outlier, was excluded). A similar relationship was found for clinical response. These results will be valuable in supporting dose selection of oritavancin for patients with S. aureus bacteremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.